Our results from mechanistic studies in HMEC, gene expression analysis of ER+/HER2- tumors from the TCGA cohort and analysis of ER+/HER2- breast tumors by IHC implicate basal activity of RelA in suppressing proliferation through upregulation of IRF1 and downregulation of CDK4. The gene discussed is IRF1; the disease is breast neoplasm.